Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
HX-009 by Waterstone Hanxbio for Metastatic Melanoma: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...
HX-009 by Waterstone Hanxbio for Solid Tumor: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Solid Tumor. According to GlobalData, Phase...
HX-009 by Waterstone Hanxbio for Biliary Tumor: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Biliary Tumor. According to GlobalData, Phase...
HX-009 by Waterstone Hanxbio for Sarcomas: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Sarcomas. According to GlobalData, Phase II...
HX-009 by Waterstone Hanxbio for Malignant Mesothelioma: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Malignant Mesothelioma. According to GlobalData, Phase...
HX-009 by Waterstone Hanxbio for Esophageal Cancer: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase...
HX-009 by Waterstone Hanxbio for Head And Neck Cancer: Likelihood of Approval
HX-009 is under clinical development by Waterstone Hanxbio and currently in Phase II for Head And Neck Cancer. According to...